Replies to post #796253 on NorthWest Biotherapeutics Inc (NWBO)

[seekinganswers]

The clowns are all talking about Big Pharma buyouts of NWBO, when all BP has to do is pay UCLA for a licensing agreement. if they wanted to expand the tech. UCLA owns all the DC research and has their own clean rooms and manufacturing.
LOL, it's all so comical. NWBO is worthless, IMO. GL to all

[ilovetech]

Gemini answer:
Conclusion: The Intentional Narrative Skew
The omission of UCLA's clinical role appears to be an editorial choice to heavily favor the narrative of manufacturing resilience and technological innovation (Eden, Flaskworks, Advent, Zeon).
The author focuses on answering the question: "How do you mass-produce instruction?" The result is a brilliant review of the engineering and supply chain, but one that sacrifices the clinical history that provided the initial justification for the entire enterprise.

Weird no mention of UCLA in this extensive review. Wonder why?

Andrew has many times over cited UCLA's clinical and pivotal role in the evolution of DCVAX.

So I would ask, where were you, when Andrew cited UCLA at nauseum in a clinical context, but pop-up here with a flippant response to serve your ego, and clearly not, to the benefit of shareholders?

[Slave1]

UCLA isn’t missing, it’s the foundation the whole story stands on. The JAMA Oncology Phase 3 trial led by Dr. Linda Liau anchors Act IV, while the Nature Biomedical Engineering and Nature Protocolspapers from Dr. Zeyang Liu and Dr. Song Li in Act VI independently validate the same mechanical laws that Eden was built to preserve.

IUCLA proved both ends of the system, that DCVax works in patients, and that Eden’s physics makes that success reproducible. And considering Dr. Liau now sits on NWBO’s Scientific Advisory Board, asking why UCLA isn’t mentioned is a bit like asking a fish if it knows it’s swimming in water.